Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc

[1]  G. Torri,et al.  Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. , 1994, Analytical biochemistry.

[2]  J. Harenberg,et al.  Binding of Heparin to Human Leukocytes , 1994 .

[3]  J. Harenberg,et al.  Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes. , 1994, Seminars in thrombosis and hemostasis.

[4]  A. Wunder,et al.  Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. , 1993, The Journal of laboratory and clinical medicine.

[5]  J. Hirsh,et al.  Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins , 1993, Thrombosis and Haemostasis.

[6]  J. Harenberg,et al.  Considerations about the Correct Nomenclature of Glycosaminoglycans (GAGs) , 1993, Thrombosis and Haemostasis.

[7]  J. C. Hurowitz.  Toward a social policy for health. , 1993, The New England journal of medicine.

[8]  D. Lane,et al.  Non-anticoagulant uses of heparin. , 1993, The New England journal of medicine.

[9]  J. Hirsh.  Low molecular weight heparin , 2007 .

[10]  G. Gervasi,et al.  Disposition of a new heparan sulfate with fibrinolytic activity in the rat. , 1993, Arzneimittel-Forschung.

[11]  D. Hoppensteadt,et al.  Biochemical and pharmacologic profile of defined molecular weight fractions of heparin. , 1993, Seminars in thrombosis and hemostasis.

[12]  A. Wunder,et al.  Hepatic uptake of a modified low molecular weight heparin in rats. , 1992, The Journal of clinical investigation.

[13]  G. Houin,et al.  Pharmacological Properties of a Low Molecular Weight Butyryl Heparin Derivative (C4-CY 216) with Long Lasting Effects , 1992, Thrombosis and Haemostasis.

[14]  G. Houin,et al.  Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects. , 1992, The Journal of laboratory and clinical medicine.

[15]  D. Bergqvist,et al.  Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. , 1991, Thrombosis research.

[16]  A. Al-Hakim,et al.  Acidic Polysaccharides: Their Modification and Potential Uses , 1991 .

[17]  J. Dawes.  Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. , 1990, Acta chirurgica Scandinavica. Supplementum.

[18]  G. Houin,et al.  Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the Rabbit , 1989, Thrombosis and Haemostasis.

[19]  G. Houin,et al.  Pharmacokinetics of Heparin and Related Polysaccharides a , 1989, Annals of the New York Academy of Sciences.

[20]  M. Scully,et al.  Influence of Whole Blood on Standard Curve for Heparin Measurement - Possible Heparin Binding by Red Cells , 1989, Thrombosis and Haemostasis.

[21]  J. Harenberg,et al.  Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. , 1989, Haemostasis.

[22]  L. Leung,et al.  Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effects of histidine-rich glycoprotein. , 1989, Blood.

[23]  J. Harenberg,et al.  Pharmacology and special clinical applications of low‐molecular‐weight heparins , 1988, American journal of hematology.

[24]  T. Barrowcliffe,et al.  An International Standard for Low Molecular Weight Heparin , 1988, Thrombosis and Haemostasis.

[25]  M. Anne,et al.  Influence of Heparin and a Low Molecular Weight Heparin Fraction of the Leukocytes in an Experimental Venous Thrombosis Model , 1987, Journal of leukocyte biology.

[26]  M. Ruggiero,et al.  Internalization and metabolism of endogenous heparin by cultured endothelial cells. , 1986, Biochemical and biophysical research communications.

[27]  O. Larm,et al.  A new method for covalent coupling of heparin and other glycosaminoglycans to substances containing primary amino groups. , 1983, Carbohydrate research.

[28]  J. Harenberg,et al.  CHARACTERIZATION OF HEPARINS BY HIGH-PERFORMANCE SIZE EXCLUSION LIQUID CHROMATOGRAPHY , 1983 .

[29]  D. Horton,et al.  The nitrous acid deamination of glycosides and acetates of 2-amino-2-deoxy-D-glucose , 1973 .

[30]  G. Minot.  FOREWORD to Blood, The Journal of Hematology , 1946 .